Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Enzyme Inhibition

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.

Enzymes

Enzymes

Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Target-driven machine learning-enabled virtual screening (TAME-VS) enables prioritization of AKR1C3 inhibitors.

Communications chemistry·2026

Same author

Engineering sharp-tip bimetallic nanozymes onto motif-designed two-dimensional peptide biomatrices for multimodal breast Cancer therapy.

Journal of colloid and interface science·2026

Same author

Fructose 1-phosphate inhibits mannose phosphate isomerase to suppress hepatocellular carcinogenesis.

Signal transduction and targeted therapy·2026

Same author

A coumarin-based fluorescent probe for viscosity imaging: photophysical characterization and applications in living cells.

Analytica chimica acta·2026

Same author

Motif-designed peptide nanofibers as bioactive surface modifiers for biomimetic hydroxyapatite formation on demineralized porous dentin.

RSC advances·2026

Same author

The naked mole-rat cGAS promotes homologous recombination repair and delays aging.

Science bulletin·2026

Same journal

Recent advances in 1,3,5-triazine-based PI3K inhibitors for cancer therapy: a comprehensive review.

Future medicinal chemistry·2026

Same journal

Indole-based carbohydrazides as potent anti-proliferative leads and tubulin polymerization inhibitors: design, synthesis, cytotoxic evaluation, <i>in silico</i> ADMET and docking studies.

Future medicinal chemistry·2026

Same journal

Recent advances in the development of small molecule STK33 inhibitors.

Future medicinal chemistry·2026

Same journal

Biological evaluation and molecular docking of previously reported pyrazolo-thiazole derivatives as dual α-amylase and α-glucosidase inhibitors.

Future medicinal chemistry·2026

Same journal

Coumarin derivatives as antidiabetic agents: a comprehensive review on mechanistic insights, structure-activity relationships, <i>in silico</i> studies, and challenges.

Future medicinal chemistry·2026

Same journal

Expanding the tetrazole space: medicinal chemistry, biological diversity and structure-activity relationships.

Future medicinal chemistry·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Nov 21, 2025

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Achieving effective and selective CK1 inhibitors through structure modification.

Chenxi Du¹, Hongyu Yang¹, Feng Feng^2,3

¹Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.

Future Medicinal Chemistry

|January 13, 2021

Summary

This summary is machine-generated.

Developing selective Casein kinase 1 (CK1) inhibitors is challenging due to isoform similarity. This study reviews existing CK1 inhibitors to guide future structure-based drug design for improved efficacy and selectivity.

Keywords:

Wnt signaling cancer casein kinase 1 selective kinase inhibitors structure modification structure-based drug design

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α

Published on: November 2, 2018

Related Experiment Videos

Last Updated: Nov 21, 2025

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α

Published on: November 2, 2018

Area of Science:

Biochemistry
Pharmacology
Drug Discovery

Background:

Casein kinase 1 (CK1) is a serine/threonine kinase family with six human isoforms.
CK1 plays a role in numerous biological processes, making it a therapeutic target for diseases like cancer, inflammation, and neurodegenerative disorders.
The structural similarity among CK1 isoforms complicates the development of selective inhibitors.

Purpose of the Study:

To analyze existing Casein kinase 1 (CK1) inhibitors.
To provide insights for structure-based drug design of novel CK1 inhibitors.
To guide rational structure modification for enhanced inhibitor efficacy and selectivity.

Main Methods:

Review and analysis of published CK1 inhibitor structures and their design strategies.
Examination of structure-activity relationships for known CK1 inhibitors.
Comparative analysis of inhibitor selectivity across CK1 isoforms.

Main Results:

Several CK1 inhibitors offer valuable lessons for drug design.
Structure-based approaches have yielded insights into achieving selectivity.
Modification strategies can improve inhibitor effectiveness.

Conclusions:

Further research into structure-based drug design is crucial for developing effective and selective CK1 inhibitors.
Lessons learned from current inhibitors can accelerate the discovery of new therapeutic agents.
Targeting CK1 remains a promising avenue for treating various pathological conditions.